Clinical Trial Search

Primary: Blood Pressure Following Oxymetazoline Administration — 102; 53; 65 mmHg

Primary: Insomnia Severity Index (ISI) — 11 score on a scale

Primary: Pathologic Complete Response Rate (ypCR) Following Neoadjuvant Therapy in Breast and Axillary Lymph Nodes — 26.3; 16.7 percentage of participants

Primary: Arm A: Percentage of Complete Responses — 46 percentage of participants

Primary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts on the Face — -60.84; -62.17 percentage change in lesion counts — p=0.5947

Primary: Faces Pain Scale-Revised (FPS-R) — 4; 2 units on a scale

Primary: Number of Patients With Complete (CR), Partial (PR), or Minor (MR) Response and Without Progressive Disease — 28 Participants

Primary: Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies — 63; 53 Participants

Primary: (IUD Insertion): Pain Perceived by Visual Analogue Scale (0-100 mm) Immediately Following Procedure Completion — 65; 59 score on a scale

Primary: Mean Change From Baseline in HbA1c at Week 24 — -1.67; -1.54 % HbA1c — p=0.118

Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per 24 Hours — -0.90; -1.35 micturitions — p=<0.001

Primary: Wound Complications — 3; 2 Participants

Primary: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS) — 19.6; 46.4; 75.8 percentage of participants — p=< 0.001

Primary: Number of Participants With at Least One Side Effect, Adverse Event, and Serious Adverse Event — 20; 17; 12; 11 Participants

Primary: Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 — 163; 1; 150; 2 Participants